Clinical Trials Directory

Trials / Unknown

UnknownNCT06289777

Aortic Remodeling After Endovascular Management of Type B Aortic Dissection.

Status
Unknown
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers

Summary

Assess the clinical outcome, morphological changes and behaviour of type B aortic dissection after endovascular repair.

Detailed description

Aortic dissection (AD) is considered the most common catastrophic event of the aorta, and its incidence has been reported to be ≈3/100000 per year, exceeding that of ruptured abdominal aortic aneurysm. AD is a dynamic process and can occur anywhere along the course of the aorta, with the pathognomonic lesion being an intimal tear followed by blood surging either antegrade (typically) or retrograde, cleaving the the intima and medial layers of the aortic wall longitudinally for a variable distance, thus creating a true and false lumens. Aortic dissections are classified by chronicity, anatomic location of false lumen, generally the entry tear and longitudinal extent, and the presence or absence of complicating features. Temporally, AD is categorized as acute phase {\<14 days}, subacute {15-90 days}, and chronic {\>90 days}. Thoracic Endovascular Aortic Repair (TEVAR) has emerged as the first-line therapy for the treatment of AD, with better short-term results than open repair due to a significant decrease in perioperative morbidity and mortality. By covering the primary entry tear with stent-grafts, the blood flow is redirected into the true lumen, resolving malperfusion and/or preventing rupture of the false lumen, followed by its regression and re-expansion of the true lumen, which is known as "Aortic remodeling"

Conditions

Interventions

TypeNameDescription
PROCEDURETEVARminimally invasive endovascular intervention to treat aortic dissection

Timeline

Start date
2024-03-01
Primary completion
2026-03-01
Completion
2026-04-01
First posted
2024-03-04
Last updated
2024-03-04

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06289777. Inclusion in this directory is not an endorsement.